Forthcoming Issue

Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.

Online First

Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.

Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.

Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections.  You may also view the abstract by clicking on the article link.

Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.

Editor’s Letter

Fourth and final issue of GaBI Journal’s 10th volume / Professor Philip D Walson, MD

Letters to the Editor

No need for systematic switch studies to demonstrate interchangeability of biosimilars / Professor Pekka Kurki, MD, PhD, Finland

Original Research

Extended stability of the trastuzumab biosimilar ABP 980 (KANJINTI®) in polyolefin bags and elastomeric devices / Lyndsay Davies, PhD; Katie Milligan, BSc; Mark Corris, BSc; Ian Clarke1; Paul Dwyer, MSc; Sarah Elizabeth Lee, PhD; Jolene Teraoka, BSc; Jill Crouse-Zeineddini, PhD; Jane Hippenmeyer, PharmD

Review Articles

The European framework for intellectual property rights for biological medicines / Josette Sciberras, MBA, MA Bioethics, BPharm (Hons); Raymond Zammit, SThD; Patricia Vella Bonanno, PhD

Biotechnological therapies and biosimilars for COVID-19: scarcities, poor regulation, and pharmaceutical black market: a case analysis in Ecuador / Esteban Ortiz-Prado, MD, MSc, MPH, PhD; Enrique Teran, MD, PhD; Raul Patricio Fernandez Naranjo, MSc; Doménica Cevallos-Robalino, MD; Eduardo Vasconez1, MD; Alex Lister, MPH


Biosimilarity is not transitivity: implication on interchangeability, naming and pharmacovigilance / Pablo Matar, PhD, Argentina


Regulatory pathway for approval of ‘biosimilars’ in Iran / Jalal Naeli, MD

Click here for more details on the educational series.

Contact us for an updated list of editorial topics in forthcoming issues.

*Editorial content may differ from final version of manuscript published in print.

Source URL:

Generics and Biosimilars Initiative (GaBI)
Tel: +32 474989572 | Fax: +32 14 583 048